Both AstraZeneca/Bristol Diabetes Drugs Should Meet FDA Guidance
AstraZeneca execs maintain during earnings call that clinical trial programs for dapagliflozin and saxagliptin satisfy new regulatory requirements.
AstraZeneca execs maintain during earnings call that clinical trial programs for dapagliflozin and saxagliptin satisfy new regulatory requirements.